What is CytomX Therapeutics Inc Annual Revenue?

CytomX Therapeutics Inc Annual Revenue rose 36.45%, in the last year to $138.1 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is CytomX Therapeutics Inc Annual Net Profit?

CytomX Therapeutics Inc Annual Net Profit rose 5,700.88% in the last year to $31.87 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is CytomX Therapeutics Inc Price to Earning Ratio?

CytomX Therapeutics Inc Price to Earning Ratio is 1.89, lower than its sector PE ratio of 3.14.

What is CytomX Therapeutics Inc Stock Price?

CytomX Therapeutics Inc Stock Price fell 55.09% and underperformed its sector by 61.9% in the past year.

What is CytomX Therapeutics Inc Quarterly Revenue?

CytomX Therapeutics Inc Quarterly Revenue rose 43.17% YoY to $38.09 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is CytomX Therapeutics Inc Quarterly Net profit?

CytomX Therapeutics Inc Quarterly Net profit rose 2,155.2% YoY to $18.88 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is CytomX Therapeutics Inc Mutual Fund Holding?

CytomX Therapeutics Inc Mutual Fund Holding decreased by 0.5% in the last quarter to 15.34.

What is CytomX Therapeutics Inc Promoter Share Holding?

CytomX Therapeutics Inc Promoter Share Holding increased by 1.1% in the most recent quarter to 3.17%.

What is CytomX Therapeutics Inc Institutional Holding?

CytomX Therapeutics Inc Institutional Holding increased by 0.14% in the last quarter to 54.59.

How is the CytomX Therapeutics Inc today?

The CytomX Therapeutics Inc today is trading in the green, up by 13.64% at 0.75.

How has CytomX Therapeutics Inc performed historically?

The CytomX Therapeutics Inc is currently trading up 13.64% on an intraday basis in the past week the index rose 41.51%. The index has been down -10.71% in the past quarter and fell -55.09% in the past year. You can view this in the overview section.

CytomX Therapeutics Inc XNAS: CTMX

CytomX Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: CytomX Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: CytomX Therapeutics Inc
Rating: 2.08683325
Author: Trendlyne DVM scores

Download real time

0.75 0.09 (13.64%)

87.18% Fall from 52W High

1.7M XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

CytomX Therapeutics Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	60.1
PE TTM High in industry Unavailable in chosen country	1.9
Price to Book Negative Price to Book Unavailable in chosen country	-131.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	54.6
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	43.2
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	36.4
Net Profit Qtr Growth YoY % Market Leader Unavailable in chosen country	2,155.2
Net Profit TTM Growth % Market Leader Unavailable in chosen country	5,700.9
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	46.4
Operating Profit Margin TTM % High in industry Unavailable in chosen country	18.1
Piotroski Score High in industry Unavailable in chosen country	5
Rel Perf vs Sector quarter% Unavailable in chosen country	-10.1
RoA Annual % High in industry Unavailable in chosen country	19.8

All financials are in USD Million and price data in USD

Not Eligible

Mid Valuation

46.8 / 100

Technically Neutral

36.6 / 100

1Yr Price target upside is 533%

4 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Buy Zone

13.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

CytomX Therapeutics Inc Stock Price Analysis

Day Price Range 13.6% 1 Day return Unavailable in chosen country	0.8 (LTP) 0.60.8 LowHigh
Week Price Range 41.5% 1 Week return Unavailable in chosen country	0.8 (LTP) 0.50.8 LowHigh
Month Price Range 11.9% 1 Month return Unavailable in chosen country	0.8 (LTP) 0.40.8 LowHigh
52 Week Price Range -55.1% 1 Year return Unavailable in chosen country	0.8 (LTP) 0.45.8 LowHigh

View full Share Price History

CytomX Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

CytomX Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.4

Avg. Estimate

0.3

Low Estimate

High Estimate

0.8

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 18.4% in FY25

Consensus Recommendation

6 ANALYST Recommendations

BUY

The consensus recommendation from 6 analysts for CytomX Therapeutics Inc is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

CytomX Therapeutics Inc Stock Analysis

CytomX Therapeutics Inc stock analysis with key metrics, changes, and trends.

CytomX Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$138.1 M	36.45%	positive	Annual Revenue rose 36.45%, in the last year to $138.1 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$31.87 M	5700.88%	positive	Annual Net Profit rose 5,700.88% in the last year to $31.87 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	1.89	-	positive	Price to Earning Ratio is 1.89, lower than its sector PE ratio of 3.14.
Stock Price	$0.75	-55.09%	negative	Stock Price fell 55.09% and underperformed its sector by 61.9% in the past year.
Quarterly Revenue	$38.09 M	43.17%	positive	Quarterly Revenue rose 43.17% YoY to $38.09 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$18.88 M	2155.2%	positive	Quarterly Net profit rose 2,155.2% YoY to $18.88 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Mutual Fund Holding	15.34 %	-0.5%	negative	Mutual Fund Holding decreased by 0.5% in the last quarter to 15.34.
Promoter Share Holding	3.17 %	1.1%	positive	Promoter Share Holding increased by 1.1% in the most recent quarter to 3.17%.
Institutional Holding	54.59 %	0.14%	positive	Institutional Holding increased by 0.14% in the last quarter to 54.59.

VIEW LESS

Loading data..

CytomX Therapeutics Inc - Company Profile

What does CytomX Therapeutics Inc do?

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc Management structure

All Gross Remunerations are in USD

Mr. Jeffrey B. Landau

Senior Vice President, Chief Business Officer, and Head of Strategy

2025

Gross Remuneration

2024

Gross Remuneration

Year

CytomX Therapeutics Inc Live Share Price Today, Share Analysis and Chart

87.18% Fall from 52W High

CytomX Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

RoA Annual %

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

CytomX Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

CytomX Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

CytomX Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to reduce by 18.4% in FY25

Consensus Recommendation

The consensus recommendation from 6 analysts for CytomX Therapeutics Inc is BUY

CytomX Therapeutics Inc Stock Analysis

CytomX Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 36.45%, in the last year to $138.1 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit rose 5,700.88% in the last year to $31.87 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is 1.89, lower than its sector PE ratio of 3.14.

Stock Price fell 55.09% and underperformed its sector by 61.9% in the past year.

Quarterly Revenue rose 43.17% YoY to $38.09 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit rose 2,155.2% YoY to $18.88 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Mutual Fund Holding decreased by 0.5% in the last quarter to 15.34.

Promoter Share Holding increased by 1.1% in the most recent quarter to 3.17%.

Institutional Holding increased by 0.14% in the last quarter to 54.59.

CytomX Therapeutics Inc - Company Profile

What does CytomX Therapeutics Inc do?

CytomX Therapeutics Inc Management structure

Mr. Jeffrey B. Landau

Senior Vice President, Chief Business Officer, and Head of Strategy

CytomX Therapeutics Inc Board of directors

Dr. Zhen Su, M.D.

DIrector

Mr. James R. Meyers

Independent Director

Dr. Elaine V. Jones, PhD

Independent Director

Ms. Halley E. Gilbert

Independent Director

Mr. Matthew P. Young

Lead Independent Director

Dr. Sean A. McCarthy, D.Phil.

Chief Executive Officer and Chairman of the Board

CytomX Therapeutics Inc FAQ

How is CytomX Therapeutics Inc today?

CytomX Therapeutics Inc today is trading in the green, and is up by 13.64% at 0.75.

How has CytomX Therapeutics Inc performed historically?

CytomX Therapeutics Inc is currently trading up 13.64% on an intraday basis. In the past week the stock rose 41.51%. stock has been down -10.71% in the past quarter and fell -55.09% in the past year. You can view this in the overview section.